Literature DB >> 8656072

Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.

K O1, J Frohlich.   

Abstract

Lipoprotein-X (Lp-X) is an abnormal particle present in the plasma of patients with familial lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes or cholestatic liver disease. Compared to other lipoproteins, Lp-X contains a high content of unesterified cholesterol (30%, w/w) to phosphatidylcholine (60%, w/w). The objective of this study was to evaluate the role of LCAT and apolipoprotein A-I (apoA-I) in Lp-X metabolism in vitro and to elucidate the regulation of cholesterol esterification in this unique lipoprotein. Lp-X isolated from sera of patients with obstructive jaundice had a high content of unesterified cholesterol and phosphatidylcholine and contained apolipoprotein E, apoCs, and albumin. Although human recombinant LCAT used as an enzyme source did bind to isolated Lp-X, no cholesterol esterification was detected. However, addition of human apoA-I in the presence of albumin resulted in significant cholesterol esterification in Lp-X (Vmax 0.25 +/- 0.04 nmol/h per microgram LCAT protein). Exogenous apoA-I did not change the size of Lp-X particle as determined by quasi-elastic light scattering analysis. A reduction in Lp-X size was observed when both apoA-I and LCAT were included in the reaction mixture (from 47 nm to 42 nm). Furthermore, addition of apoA-I (but not HDL) dramatically changed the electrophoretic mobility of Lp-X from cathodic to anodic migration. Such changes are not due to displacement of apoC or apoE proteins from Lp-X by apoA-I. While increasing apoA-I concentration (up to 35 micrograms/ml) in the reaction mixture stimulated cholesterol esterification in Lp-X, addition of apoA-I at the concentration of 8 micrograms/ml inhibited cholesterol esterification in VLDL, LDL, and HDL by more than 50%. Albumin was required for the LCAT reaction to Lp-X. Our results suggest that while LCAT binds to isolated Lp-X, apoA-I is needed for the LCAT reaction to proceed. The presence of apoA-I does not result in the displacement of apoCs and apoE from Lp-X and addition of apoA-I changes the electrophoretic mobility but not the size of Lp-X.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8656072

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  10 in total

1.  Effect of postmenopausal hormone replacement therapy on lipoprotein and homocysteine levels in Chinese women.

Authors:  R Y Man; L K Ting; S Fan; M M Lau; Y L Siow; Y H Chung; K O
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

2.  Effect of lipoprotein-X on lipid metabolism in rat kidney.

Authors:  K O; M Ly; D Z Fang; J Frohlich; P C Choy
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

3.  LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.

Authors:  Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2018-12-18       Impact factor: 4.030

4.  Uptake and metabolism of lipoprotein-X in mesangial cells.

Authors:  E G Lynn; P C Choy; A Magil; K O
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

5.  Effect of magnesium tanshinoate B on the production of nitric oxide in endothelial cells.

Authors:  K O; F Cheung; F L Sung; D Y Zhu; Y L Siow
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

6.  Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice.

Authors:  Xavier Rousset; Boris Vaisman; Bruce Auerbach; Brian R Krause; Reyn Homan; John Stonik; Gyorgy Csako; Robert Shamburek; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

7.  Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse.

Authors:  R P Elferink; R Ottenhoff; J van Marle; C M Frijters; A J Smith; A K Groen
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

8.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

9.  ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid.

Authors:  Edward B Neufeld; Masaki Sato; Scott M Gordon; Vinay Durbhakula; Nicolas Francone; Angel Aponte; Gizem Yilmaz; Denis Sviridov; Maureen Sampson; Jingrong Tang; Milton Pryor; Alan T Remaley
Journal:  Biology (Basel)       Date:  2019-07-12

10.  Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma.

Authors:  Yi Guo; Yong-Gen Zhang; Hong-Chun Li; Yin-Hai Xu
Journal:  Onco Targets Ther       Date:  2021-02-15       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.